ClinicalTrials.gg
CompletedNCT02196714Updated Apr 26, 2017Results posted

PK Study of PT003 and PT001 in Japanese Healthy Subjects

A Phase 1 interventional study of Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 and Glycopyrronium and Formoterol Fumarate (GFF) Dose 2 in COPD, sponsored by Pearl Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-26.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
173rd of 194
24 · median 137
Started
2014
with 13 others
Phase 1
42 of 284
none open now
Registered
156th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 173rd largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 42 in phase 1, and was the 156th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over, Single-Center, Phase I, Crossover Study in Healthy Japanese Adult Subjects to Evaluate the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001.

03

Conditions studied

  • COPD

Keywords

  • Japanese Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Form (ICF) prior to any study related procedures

  • Male and female first generation Japanese subjects 18 to 45 years, inclusive
  • Good general health
  • Medically acceptable for women of and males with female partners of childbearing potential
  • Clinical labs within normal ranges or determined to be not by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, nursing female subjects, or subjects trying to conceive
  • neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study
  • History of abnormalities
  • Cancer not in complete remission for at least 5 years
  • Clinically significant, symptomatic prostatic hypertrophy
  • Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening
  • Clinically significant bladder neck obstruction or urinary retention
  • Inadequately treated glaucoma
  • History of an allergic reaction or to any drug or to any component of the formulations used in this study
  • Subjects with pre-existing anemia and/or iron deficiency
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Glycopyrronium and Formoterol Fumarate (GFF) Dose 1

    Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)

    Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1

  • Experimental
    Glycopyrronium and Formoterol Fumarate (GFF) Dose 2

    Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)

    Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 2

  • Experimental
    Glycopyrronium (GP) Dose 1

    Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)

    Drug: Glycopyrronium (GP) Dose 1

  • Experimental
    Glycopyrronium (GP) Dose 2

    Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)

    Drug: Glycopyrronium (GP) Dose 2

Interventions

  • DrugGlycopyrronium and Formoterol Fumarate (GFF) Dose 1

    Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)

  • DrugGlycopyrronium and Formoterol Fumarate (GFF) Dose 2

    Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)

  • DrugGlycopyrronium (GP) Dose 1

    Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)

  • DrugGlycopyrronium (GP) Dose 2

    Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)

06

What researchers measure

Primary outcomes

  1. Cmax

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (Cmax)

    Time frame: Day 1

  2. Cmax

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (Cmax)

    Time frame: Day 1

  3. AUC 0-12

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-12)

    Time frame: Day 1

  4. AUC 0-12

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-12)

    Time frame: Day 1

  5. AUC 0-t

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-t)

    Time frame: Day 1

  6. AUC 0-t

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-t)

    Time frame: Day 1

  7. AUC 0-∞

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-∞)

    Time frame: Day 1

  8. AUC 0-∞

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-∞)

    Time frame: Day 1

  9. Tmax

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (tmax)

    Time frame: Day 1

  10. Tmax

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (tmax)

    Time frame: Day 1

  11. T 1/2

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (T 1/2)

    Time frame: Day 1

  12. T 1/2

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (T 1/2)

    Time frame: Day 1

  13. CL/F

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment

    Time frame: Day 1

  14. CL/F

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment

    Time frame: Day 1

  15. Vd/F

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrroniuml by Treatment

    Time frame: Day 1

  16. Vd/F

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment

    Time frame: Day 1

  17. Lambda z

    Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment

    Time frame: Day 1

  18. Lambda z

    Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment

    Time frame: Day 1

Secondary outcomes

  1. Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose

    Time frame: 12 Hours

  2. Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar volume)

    Time frame: 12 Hours

  3. Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar hemoglobin)

    Time frame: 12 Hours

  4. Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Erythrocytes)

    Time frame: 12 Hours

  5. Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose

    Time frame: 12 hours

  6. Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (eGFR)

    Time frame: 12 hours

  7. Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ferritin)

    Time frame: 12 hours

  8. Change in Mean Glucose and Potassium Results (±SD) From Pre-dose to 12 Hours Post-dose

    Change in Mean Glucose and Potassium Results (±SD) from Pre-dose to 12 Hours Post-dose

    Time frame: 12 hours

  9. Change in Heart Rate From Pre-dose to 12 Hours Post Dose

    Change in Heart Rate from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

  10. Change in PR Interval From Pre-dose to 12 Hours Post Dose

    Change in PR Interval from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

  11. Change in QRS Axis From Pre-dose to 12 Hours Post Dose

    Change in QRS axis from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

  12. Change in QRS Duration From Pre-dose to 12 Hours Post Dose

    Change in QRS duration from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

  13. Change in QT Interval From Pre-dose to 12 Hours Post Dose

    Change in QT Interval from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

  14. Change in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose

    Change in QTc Bazett Interval from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

  15. Change in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose

    Change in QTc Fridericia's Interval from Pre-dose to 12 hours Post dose

    Time frame: 12 hours

07

Results

Posted Apr 26, 2017

Participant flow

Conducted at 1 site from July 2014 - September 2014. Study duration for each subject was between 33 and 98 days.

Participant flow — Overall Study
MilestoneReceived GFF MDI 28.8/9.6 μgReceived GFF MDI 14.4/9.6 μgReceived GP MDI 28.8 μgReceived GP MDI 14.4 μg
Started24232424
Completed24232324
Not completed0010
Withdrew: Protocol violation0010

Outcome measures

PrimaryCmax

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (Cmax)

Time frame:
Day 1
Reported as:
Mean · pg/mL
Cmax
pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 µg
Cmax15.23 ± 7.699.09 ± 6.516.85 ± 4.267.26 (2.51 to 16.10)
PrimaryCmax

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (Cmax)

Time frame:
Day 1
Reported as:
Mean · pg/mL
Cmax
pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
Cmax10.74 ± 3.4611.99 ± 7.07
PrimaryAUC 0-12

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-12)

Time frame:
Day 1
Reported as:
Mean · h*pg/mL
AUC 0-12
h*pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 ug
AUC 0-1245.43 ± 19.4321.75 ± 9.0050.59 ± 10.7524.72 (7.63 to 51.06)
PrimaryAUC 0-12

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-12)

Time frame:
Day 1
Reported as:
Mean · h*pg/mL
AUC 0-12
h*pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
AUC 0-1244.15 ± 15.342.54 ± 12.04
PrimaryAUC 0-t

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-t)

Time frame:
Day 1
Reported as:
Mean · h*pg/mL
AUC 0-t
h*pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 µg
AUC 0-t53.52 ± 3.3121.37 ± 14.5364.05 ± 17.6123.72 (5.27 to 68.02)
PrimaryAUC 0-t

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-t)

Time frame:
Day 1
Reported as:
Mean · h*pg/mL
AUC 0-t
h*pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
AUC 0-t45.96 ± 19.8542.39 ± 14.69
PrimaryAUC 0-∞

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-∞)

Time frame:
Day 1
Reported as:
Mean · h*pg/mL
AUC 0-∞
h*pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 µgGP MDI 14.4 µg
AUC 0-∞46.26 (29.58 to 60.11)32.18 (30.24 to 34.13)37.32 (32.36 to 42.28)34.04 (33.67 to 34.64)
PrimaryAUC 0-∞

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-∞)

Time frame:
Day 1
Reported as:
Mean · h*pg/mL
AUC 0-∞
h*pg/mLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
AUC 0-∞61.88 ± 21.6061.43 ± 12.01
PrimaryTmax

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (tmax)

Time frame:
Day 1
Reported as:
Mean · h
Tmax
hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 ug
Tmax0.10 (0.03 to 4.02)0.10 (0.03 to 0.10)0.10 (0.03 to 2.00)0.10 (0.03 to 4.10)
PrimaryTmax

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (tmax)

Time frame:
Day 1
Reported as:
Mean · h
Tmax
hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
Tmax0.10 (0.10 to 1.00)0.10 (0.10 to 2.00)
PrimaryT 1/2

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (T 1/2)

Time frame:
Day 1
Reported as:
Mean · h
T 1/2
hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 ug
T 1/29.49 ± 11.984.14 ± 1.4024.87 ± 51.7719.13 (2.08 to 191.29)
PrimaryT 1/2

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (T 1/2)

Time frame:
Day 1
Reported as:
Mean · h
T 1/2
hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
T 1/25.45 ± 2.395.25 ± 2.32
PrimaryCL/F

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment

Time frame:
Day 1
Reported as:
Mean · L/h
CL/F
L/hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 µgGP MDI 14.4 µg
CL/F657.91 (479.15 to 973.62)449.10 (421.97 to 476.24)785.60 (681.20 to 890.00)423.12 (415.74 to 427.70)
PrimaryCL/F

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment

Time frame:
Day 1
Reported as:
Mean · L/h
CL/F
L/hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
CL/F168.95 ± 45.28161.55 ± 30.17
PrimaryVd/F

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrroniuml by Treatment

Time frame:
Day 1
Reported as:
Mean · L
Vd/F
LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 µgGP MDI 14.4 µg
Vd/F3508.00 (2089.69 to 4654.28)2577.78 (2475.12 to 2680.44)3555.88 (3509.62 to 3602.14)2101.03 (1929.07 to 2193.02)
PrimaryVd/F

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment

Time frame:
Day 1
Reported as:
Mean · L
Vd/F
LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
Vd/F1187.75 ± 313.201054.16 ± 225.15
PrimaryLambda z

Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment

Time frame:
Day 1
Reported as:
Mean · 1/h
Lambda z
1/hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 ug
Lambda z0.1506 ± 7.690.1983 ± 6.50.1100 ± 4.260.1614 (0.0036 to 0.3333)
PrimaryLambda z

Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment

Time frame:
Day 1
Reported as:
Mean · 1/h
Lambda z
1/hGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ug
Lambda z0.1412 ± 0.03810.1470 ± 0.0410
SecondaryChange in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 Hours
Reported as:
Mean · 10^9cells/L
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
10^9cells/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Basophils (10^9cells/L)0.007 ± 0.0250.000 ± 0.0220.001 ± 0.028
Eosinophils (10^9cells/L)0.044 ± 0.0480.033 ± 0.0680.065 ± 0.103
Granulocytes (10^9cells/L)0.222 ± 1.4360.483 ± 1.7930.443 ± 1.278
Leukocytes (10^9cells/L)0.484 ± 1.7100.780 ± 1.9900.800 ± 1.526
Lymphocytes (10^9cells/L)0.147 ± 0.3900.206 ± 0.4020.235 ± 0.383
Monocytes (10^9cells/L)0.065 ± 0.0840.056 ± 0.1150.055 ± 0.103
Platelets (10^9cells/L)-22.4 ± 24.5-14.4 ± 16.2-23.1 ± 26.6
SecondaryChange in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 Hours
Reported as:
Mean · Ratio
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
RatioGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Basophils/leukocytes (ratio)-0.0001 ± 0.0044-0.0013 ± 0.0040-0.0013 ± 0.0039
Eosinophils/leukocytes (ratio)0.0034 ± 0.00890.0026 ± 0.01310.0046 ± 0.0091
Granulocytes/leukocytes (ratio)0.0043 ± 0.06880.0003 ± 0.0818-0.0010 ± 0.0759
Hematocrit (ratio)-0.040 ± 0.022-0.041 ± 0.030-0.043 ± 0.023
Lymphocytes/leukocytes (ratio)-0.0110 ± 0.0565-0.0019 ± 0.0662-0.0018 ± 0.0616
Monocytes/leukocytes (ratio)0.0034 ± 0.01250.0004 ± 0.0136-0.0006 ± 0.0118
SecondaryChange in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 Hours
Reported as:
Mean · g/L
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
g/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Ery. mean corpuscuar HGB (g/L)12.0 ± 15.58.5 ± 13.911.4 ± 15.2
Hemoglobin (g/L)-8.81 ± 7.76-10.61 ± 9.10-10.38 ± 9.10
SecondaryChange in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar volume)

Time frame:
12 Hours
Reported as:
Mean · fL
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
fLGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose-0.9 ± 0.6-0.8 ± 0.9-0.9 ± 0.8
SecondaryChange in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar hemoglobin)

Time frame:
12 Hours
Reported as:
Mean · pg/cell
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
pg/cellGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose0.78 ± 1.290.49 ± 1.080.75 ± 1.22
SecondaryChange in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Erythrocytes)

Time frame:
12 Hours
Reported as:
Mean · 10^12cells/L
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
10^12cells/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose-0.391 ± 0.242-0.419 ± 0.326-0.433 ± 0.253
SecondaryChange in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 hours
Reported as:
Mean · IU/L
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
IU/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
ALT (IU/L)-3.1 ± 4.3-1.7 ± 3.1-2.4 ± 3.9
Alkaline phosphatase (IU/L)-5.2 ± 4.3-5.0 ± 5.1-6.0 ± 3.1
AST (IU/L)-4.2 ± 3.7-3.3 ± 2.6-3.7 ± 3.0
Gamma glutamyl transferase (IU/L)-2.5 ± 2.4-1.6 ± 1.9-2.2 ± 1.9
SecondaryChange in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 hours
Reported as:
Mean · g/L
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
g/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Albumin (g/L)-7.1 ± 2.9-6.9 ± 4.1-6.7 ± 2.4
Protein (g/L)-10.9 ± 5.3-10.8 ± 6.7-10.3 ± 4.3
SecondaryChange in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 hours
Reported as:
Mean · mmol/L
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
mmol/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Blood urea nitrogen (mmol/L)0.01 ± 1.450.34 ± 1.320.74 ± 1.51
Calcium (mmol/L)-0.15 ± 0.09-0.14 ± 0.12-0.13 ± 0.06
Chloride (mmol/L)3.0 ± 2.32.5 ± 1.82.3 ± 1.5
Magnesium (mmol/L)-0.05 ± 0.09-0.07 ± 0.09-0.04 ± 0.20
Phosphorus (mmol/L)0.135 ± 0.1650.163 ± 0.1320.133 ± 0.164
Sodium (mmol/L)0.9 ± 2.10.5 ± 1.30.1 ± 1.6
SecondaryChange in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 hours
Reported as:
Mean · μmol/L
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
μmol/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Creatinine (μmol/L)1.88 ± 11.144.92 ± 15.743.61 ± 13.41
Direct bilirubin (μmol/L)-3.06 ± 1.75-2.53 ± 1.45-2.64 ± 2.14
Iron (μmol/L)-5.42524 ± 8.9-2.81888 ± 7.07702-2.58949 ± 8.19974
Total bilirubin (μmol/L)-8.19 ± 5.68-7.14 ± 4.80-7.20 ± 5.92
SecondaryChange in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (eGFR)

Time frame:
12 hours
Reported as:
Mean · mL/min/1.73m2
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
mL/min/1.73m2GFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose-4.2 ± 13.2-7.2 ± 16.6-3.5 ± 15.3
SecondaryChange in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ferritin)

Time frame:
12 hours
Reported as:
Mean · μg/L
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
μg/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose-14.169 ± 13.912-11.949 ± 12.306-11.669 ± 9.731
SecondaryChange in Mean Glucose and Potassium Results (±SD) From Pre-dose to 12 Hours Post-dose

Change in Mean Glucose and Potassium Results (±SD) from Pre-dose to 12 Hours Post-dose

Time frame:
12 hours
Reported as:
Mean · mmol/L
Change in Mean Glucose and Potassium Results (±SD) From Pre-dose to 12 Hours Post-dose
mmol/LGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Glucose (mmol/L) 30 minutes post-dose-0.03 (-0.3 to 0.6)-0.08 (-0.8 to 0.5)-0.01 (-0.4 to 0.7)
Glucose (mmol/L) 2 hours post-dose0.05 (-0.3 to 0.4)-0.01 (-0.7 to 0.8)-0.06 (-0.4 to 0.7)
Glucose (mmol/L) 4 hours post-dose-0.08 (-0.5 to 0.4)-0.24 (-0.8 to 0.4)-0.16 (-0.6 to 0.7)
Glucose (mmol/L) 12 hours post-dose0.10 (-0.4 to 0.7)0.18 (-0.8 to 0.8)0.23 (-0.3 to 0.9)
Potassium (mmol/L) 30 minutes post-dose0.01 (-0.3 to 1.0)0.00 (-0.6 to 0.5)0.06 (-0.5 to 0.9)
Potassium (mmol/L) 2 hours post-dose-0.02 (-0.5 to 0.8)-0.07 (-0.5 to 0.4)0.10 (-0.4 to 2.4)
Potassium (mmol/L) 4 hours post-dose-0.01 (-0.6 to 1.0)-0.12 (-0.5 to 0.4)-0.07 (-0.6 to 0.4)
Potassium (mmol/L) 12 hours post-dose0.05 (-0.5 to 0.7)-0.06 (-0.6 to 0.4)0.07 (-0.5 to 1.0)
SecondaryChange in Heart Rate From Pre-dose to 12 Hours Post Dose

Change in Heart Rate from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · Beats/Min
Change in Heart Rate From Pre-dose to 12 Hours Post Dose
Beats/MinGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in Heart Rate From Pre-dose to 12 Hours Post Dose11.3 (2 to 42)9.3 (-4 to 36)4.5 (-13 to 29)
SecondaryChange in PR Interval From Pre-dose to 12 Hours Post Dose

Change in PR Interval from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · msec
Change in PR Interval From Pre-dose to 12 Hours Post Dose
msecGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in PR Interval From Pre-dose to 12 Hours Post Dose-10.7 (-22 to 6)-8.5 (-46 to 14)-7.4 (-36 to 6)
SecondaryChange in QRS Axis From Pre-dose to 12 Hours Post Dose

Change in QRS axis from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · QRS axis
Change in QRS Axis From Pre-dose to 12 Hours Post Dose
QRS axisGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in QRS Axis From Pre-dose to 12 Hours Post Dose-0.5 (-20 to 15)4.1 (-11 to 76)0.0 (-21 to 16)
SecondaryChange in QRS Duration From Pre-dose to 12 Hours Post Dose

Change in QRS duration from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · msec
Change in QRS Duration From Pre-dose to 12 Hours Post Dose
msecGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in QRS Duration From Pre-dose to 12 Hours Post Dose-3.9 (-24 to 8)-1.1 (-14 to 6)-4.0 (-22 to 4)
SecondaryChange in QT Interval From Pre-dose to 12 Hours Post Dose

Change in QT Interval from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · msec
Change in QT Interval From Pre-dose to 12 Hours Post Dose
msecGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in QT Interval From Pre-dose to 12 Hours Post Dose-28.5 (-64 to 0)-24.8 (-78 to 0)-20.5 (-72 to 24)
SecondaryChange in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose

Change in QTc Bazett Interval from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · msec
Change in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose
msecGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose7.2 (-14 to 40)4.4 (-26 to 30)-5.8 (-28 to 10)
SecondaryChange in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose

Change in QTc Fridericia's Interval from Pre-dose to 12 hours Post dose

Time frame:
12 hours
Reported as:
Mean · msec
Change in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose
msecGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ug
Change in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose-4.8 (-17 to 11)-5.4 (-27 to 16)-10.8 (-29 to 5)

Adverse events

Collected over Adverse Events were collected from Day 0 (Randomization visit and first dose) through Final Follow-up Visit, which is 7-14 days post final dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GFF MDI 28.8/9.6 ug—0/24 (0%)2/24 (8.3%)
GFF MDI 14.4/9.6 ug—0/23 (0%)8/23 (34.8%)
GP MDI 28.8 ug—0/24 (0%)4/24 (16.7%)
GP MDI 14.4 µg—0/24 (0%)4/24 (16.7%)
Most frequent other events
Most frequent other events
EventGFF MDI 28.8/9.6 ugGFF MDI 14.4/9.6 ugGP MDI 28.8 ugGP MDI 14.4 µg
DizzinessNervous system disorders0/242/232/240/24
HeadacheNervous system disorders0/242/231/241/24
DysmenorrhoeaReproductive system and breast disorders0/242/230/241/24
AnaemiaBlood and lymphatic system disorders0/242/231/242/24
SomnolenceNervous system disorders2/240/230/240/24

Baseline characteristics

Analysis Set: All Subjects Randomized

Age, Continuous
Age, Continuous(Years)All Subjects
Mean29.8 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female11
Male13
08

Study locations

1 site
  • SNBL
    Baltimore, Maryland 21201, United States
09

References and documents

Publications

  • Reisner C, Miller J, DePetrillo P, Maes A, Siddiqui S, Martin UJ. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. Pulm Pharmacol Ther. 2018 Dec;53:33-38. doi: 10.1016/j.pupt.2018.09.005. Epub 2018 Sep 13. PubMed 30218695 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014 and a primary completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2014
First posted
Jul 22, 2014
Start
Jul 2014
Primary completionActual
Sep 2014
Results first posted
Apr 26, 2017
Last update
Apr 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02196714
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Jul 2014
Primary completion
Sep 2014
Results posted
Apr 26, 2017
Last update
Apr 26, 2017

Study contacts

Chadwick Orevillo
study chair · Pearl Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion